Arvaya Healthcare will acquire 100% of Sushodha Institute of Gastroenterology for ₹15.49 crore through a share swap. The company also plans to raise up to ₹210 crore via a Rights Issue.
Arvaya Healthcare Acquires SIGPL for ₹15.49 Crore, Plans ₹210 Crore Rights Issue
Arvaya Healthcare Ltd has announced the acquisition of 100% of Sushodha Institute of Gastroenterology Private Limited (SIGPL) for ₹15.49 crore and a planned Rights Issue of up to ₹210 crore.
Reader Takeaway: Acquisition boosts hospital footprint; Rights Issue aims to fund growth, but risks include related-party transactions.
What just happened
The Board of Arvaya Healthcare has approved the acquisition of the entire equity stake in Sushodha Institute of Gastroenterology Private Limited (SIGPL). The acquisition will be carried out through a share swap, involving the issuance of 38,71,854 equity shares of Arvaya Healthcare at ₹40 each to the SIGPL shareholders.
Separately, the company also authorized the formation of a Rights Issue Committee to raise up to ₹210 crore through a Rights Issue to eligible equity shareholders.
Why this matters
This dual move signifies Arvaya Healthcare's intent for inorganic growth and capital strengthening. The SIGPL acquisition aims to expand the company's hospital and diagnostic network, particularly in gastroenterology. The Rights Issue proceeds are expected to fuel further expansion and operational enhancements. However, the acquisition involves related parties, necessitating careful scrutiny.
The backstory
Sushodha Institute of Gastroenterology Private Limited (SIGPL) operates a specialty hospital focused on gastroenterology and digestive diseases in Shivamogga. The company has shown consistent turnover growth, projected to increase from ₹6.36 crore in FY24 to ₹8.99 crore in FY26. Arvaya Healthcare is looking to leverage SIGPL’s established presence and expertise.
What changes now
Upon successful completion, SIGPL will become a wholly-owned subsidiary of Arvaya Healthcare, integrating its operations and financial results. The share issuance for the acquisition will lead to equity dilution for existing shareholders. The proposed Rights Issue, if fully subscribed, will significantly increase the company's capital base.
Risks to watch
The key concern is the related-party nature of the SIGPL acquisition, as common directors and shareholders exist in both entities. While the company claims an arm's length transaction based on valuation reports, governance transparency and fair pricing are crucial. The transaction is also subject to shareholder and regulatory approvals, indicating execution risk.
Peer comparison
Arvaya Healthcare operates in the healthcare services sector. Competitors include hospitals and diagnostic chains focused on various specialities. Acquisitions and capital raises are common strategies in this sector for expanding reach and service offerings.
Context metrics (time-bound)
SIGPL's turnover is projected to grow from ₹6.36 crore in FY24 to ₹7.78 crore in FY25 and ₹8.99 crore in FY26.
The acquisition consideration is ₹15.49 crore, involving the issuance of 38,71,854 shares at ₹40 per share.
The Rights Issue aims to raise up to ₹210 crore.
What to track next
Investors should closely monitor the outcomes of the postal ballot for shareholder approval of the acquisition and the terms of the Rights Issue. The progress of regulatory approvals and the successful integration of SIGPL will be key factors to watch.